WO2006071856A3 - Immunoglobulins comprising predominantly a man5glcnac2 glycoform - Google Patents

Immunoglobulins comprising predominantly a man5glcnac2 glycoform Download PDF

Info

Publication number
WO2006071856A3
WO2006071856A3 PCT/US2005/047042 US2005047042W WO2006071856A3 WO 2006071856 A3 WO2006071856 A3 WO 2006071856A3 US 2005047042 W US2005047042 W US 2005047042W WO 2006071856 A3 WO2006071856 A3 WO 2006071856A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycoform
immunoglobulins
predominantly
relates
present
Prior art date
Application number
PCT/US2005/047042
Other languages
French (fr)
Other versions
WO2006071856A2 (en
Inventor
Tillman U Gerngross
Huijuan Li
Stefan Wildt
Original Assignee
Glycofi Inc
Tillman U Gerngross
Huijuan Li
Stefan Wildt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycofi Inc, Tillman U Gerngross, Huijuan Li, Stefan Wildt filed Critical Glycofi Inc
Publication of WO2006071856A2 publication Critical patent/WO2006071856A2/en
Publication of WO2006071856A3 publication Critical patent/WO2006071856A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Abstract

The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is Man5GlcNAc2
PCT/US2005/047042 2004-12-23 2005-12-22 Immunoglobulins comprising predominantly a man5glcnac2 glycoform WO2006071856A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US63963004P 2004-12-23 2004-12-23
US63962904P 2004-12-23 2004-12-23
US63954204P 2004-12-23 2004-12-23
US63963104P 2004-12-23 2004-12-23
US63954104P 2004-12-23 2004-12-23
US60/639,541 2004-12-23
US60/639,630 2004-12-23
US60/639,542 2004-12-23
US60/639,631 2004-12-23
US60/639,629 2004-12-23

Publications (2)

Publication Number Publication Date
WO2006071856A2 WO2006071856A2 (en) 2006-07-06
WO2006071856A3 true WO2006071856A3 (en) 2006-10-05

Family

ID=36130129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/047042 WO2006071856A2 (en) 2004-12-23 2005-12-22 Immunoglobulins comprising predominantly a man5glcnac2 glycoform

Country Status (1)

Country Link
WO (1) WO2006071856A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180002911A (en) 2005-11-04 2018-01-08 제넨테크, 인크. Use of complement pathway inhibitors to treat ocular diseases
KR20160092061A (en) 2006-11-02 2016-08-03 제넨테크, 인크. Humanized anti-factor d antibodies
NZ741494A (en) 2007-05-14 2022-11-25 Kyowa Kirin Co Ltd Methods of reducing eosinophil levels
AR066660A1 (en) 2007-05-23 2009-09-02 Genentech Inc PREVENTION AND TREATMENT OF EYE CONDITIONS ASSOCIATED WITH THEIR COMPLEMENT
JP2011512875A (en) * 2008-03-11 2011-04-28 ジェネンテック， インコーポレイテッド Antibody with enhanced ADCC function
CR20170001A (en) 2008-04-28 2017-08-10 Genentech Inc ANTI FACTOR D HUMANIZED ANTIBODIES
US20110039300A1 (en) * 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
US20110053223A1 (en) * 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
CN107318267B (en) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 Compositions and methods for treating complement-associated disorders
BR112016025312A2 (en) 2014-05-01 2017-10-17 Genentech Inc antibody variants, anti-d-factor antibody, pharmaceutical formulation, dispensing device, use of the formulation and a composition, composition and method of treating a disorder
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
CN108472382A (en) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 Anti- factor D antibody variants conjugate and application thereof
JP2018534930A (en) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド Anti-factor D antibodies and conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000879A2 (en) * 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000879A2 (en) * 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHOI B-K ET AL: "Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 100, no. 9, 29 April 2003 (2003-04-29), pages 5022 - 5027, XP002267831, ISSN: 0027-8424 *
GERNGROSS TILLMAN U: "Advances in the production of human therapeutic proteins in yeasts and filamentous fungi", NATURE BIOTECHNOLOGY, vol. 22, no. 11, November 2004 (2004-11-01), pages 1409 - 1414, XP002377616, ISSN: 1087-0156 *
NOSE M AND HANS WICZELL: "Biological significance of carbohydrate chains on monoclonal antobodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 80, 1983, pages 6632 - 6636, XP002989948, ISSN: 0027-8424 *
OGUNJIMI ABIODUN A ET AL: "High-level secretory expression of immunologically active intact antibody from the yeast Pichia pastoris", BIOTECHNOLOGY LETTERS, vol. 21, no. 6, June 1999 (1999-06-01), pages 561 - 567, XP002377506, ISSN: 0141-5492 *
SHIELDS R L ET AL: "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgammaRIII and antibody-dependent cellular toxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 277, no. 30, 26 July 2002 (2002-07-26), pages 26733 - 26740, XP002964542, ISSN: 0021-9258 *
VERVECKEN W ET AL: "IN VIVO SYNTHESIS OF MAMMALIAN-LIKE, HYBRID-TYPE N-GLYCANS IN PICHIA PASTORIS", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, WASHINGTON,DC, US, vol. 70, no. 5, May 2004 (2004-05-01), pages 2639 - 2646, XP008032109, ISSN: 0099-2240 *
WILDT S ET AL: "THE HUMANIZATION OF N-GLYCOSYLATION PATHWAYS IN YEAST", NATURE REVIEWS. MICROBIOLOGY, NATURE PUBLISHING GROUP,, GB, vol. 3, no. 2, February 2005 (2005-02-01), pages 119 - 128, XP009064525, ISSN: 1740-1526 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877462B2 (en) 2000-06-28 2014-11-04 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8883483B2 (en) 2000-06-28 2014-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US8986949B2 (en) 2003-02-20 2015-03-24 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes

Also Published As

Publication number Publication date
WO2006071856A2 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
WO2006071856A3 (en) Immunoglobulins comprising predominantly a man5glcnac2 glycoform
WO2006014683A3 (en) Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform
WO2006066568A3 (en) Antibody
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2007147122A3 (en) Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
WO2008091954A3 (en) Optimized cd40 antibodies and methods of using the same
WO2007057773A3 (en) Photoactive compounds
WO2007129895A3 (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
WO2007008583A3 (en) Improved protein expression comparison assay results and applications
WO2006020114A3 (en) Variant fc regions
IL184152A (en) Monoclonal antibodies against nkg2a, compositions comprising the same, uses thereof for the manufacture of medicaments, methods for their production and methods employing said antibodies
WO2007050569A3 (en) Polypeptide multilayer films and methods
WO2005047545A3 (en) Microarray controls
MY150621A (en) Anti-epha2 antibody
WO2002075274A3 (en) Method and kit for following neurodegenerative diseases
WO2006119056A3 (en) Lighter than air supersonic vehicle
WO2007049152A3 (en) Methods of producing stable b-lymphocytes
WO2006014726A3 (en) Immunoglobulins comprising predominantly a man5glcnac2 glycoform
EP1344827A3 (en) Antifreeze proteins from basidiomycetes
WO2008030564A3 (en) Aglycosylated antibodies and methods of making and using those antibodies
WO2004075021A3 (en) Molecular modeling methods
FR2855557B1 (en) TUYERE COMPONENT WITH INCREASED LIFETIME FOR AIRCRAFT TURBOMOTORS.
WO2005035490A3 (en) PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS
NL1021490A1 (en) Process for the preparation of a fluoropolymer.
WO2007036501A3 (en) Graft copolymer and use of the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05855577

Country of ref document: EP

Kind code of ref document: A2